A plain-language summary of two 5-Year studies on bictegravir/emtricitabine/tenofovir alafenamide in people with HIV

This Plain Language Summary of publication article (PLSP) from Future Microbiology covers two studies on the HIV treatment bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), a single pill combining three drugs. The studies evaluated the safety and effectiveness of B/F/TAF over 5 years in more than 400 people across 10 countries who were new to HIV treatment.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials’ and was published in eClinical Medicine.

Visit The Lancet using the link to read the original article.

• antiretroviral therapy
• efficacy
• HIV
• long-term
• plain-language summary
• safety
• treatment naive